These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline]. Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886 [TBL] [Abstract][Full Text] [Related]
5. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016]. Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M Orv Hetil; 2017 Feb; 158(Suppl 1):3-22. PubMed ID: 28218867 [TBL] [Abstract][Full Text] [Related]
6. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 22 September 2017]. Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M Orv Hetil; 2018 Feb; 159(Suppl 1):3-23. PubMed ID: 29478339 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure]. Hunyady B; Abonyi M; Csefkó K; Gervain J; Haragh A; Horváth G; Jancsik V; Makkai E; Müller Z; Ribiczey P; Sipos B; Szabó O; Szalay F; Szentgyörgyi L; Tornai I; Újhelyi E; Varga M; Weisz G; Makara M Orv Hetil; 2016 Aug; 157(34):1366-74. PubMed ID: 27546804 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. Yu ML J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463 [TBL] [Abstract][Full Text] [Related]
9. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225 [TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 15 October 2016]. Horváth G; Gerlei Z; Gervain J; Lengyel G; Makara M; Pár A; Rókusz L; Szalay F; Tornai I; Werling K; Hunyady B Orv Hetil; 2017 Feb; 158(Suppl 1):23-35. PubMed ID: 28218868 [TBL] [Abstract][Full Text] [Related]
11. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S; Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304 [TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 22 September 2017]. Horváth G; Gerlei Z; Gervain J; Lengyel G; Makara M; Pár A; Rókusz L; Szalay F; Tornai I; Werling K; Hunyady B Orv Hetil; 2018 Feb; 159(Suppl 1):24-37. PubMed ID: 29478340 [TBL] [Abstract][Full Text] [Related]
13. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Hunyady B; Kovács B; Battyáni Z Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354 [TBL] [Abstract][Full Text] [Related]
15. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline]. Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887 [TBL] [Abstract][Full Text] [Related]
17. [Financial burden of hepatitis C infection and its treatment]. Makara M; Hunyady B Orv Hetil; 2015 May; 156(21):862-8. PubMed ID: 26038994 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313 [TBL] [Abstract][Full Text] [Related]